Entera Bio Ltd. · NASDAQ:ENTX
Entera Bio — Investor Presentation (September 2023)
36 slides from Entera Bio's investor presentation, September 2023

Slide 1: Entera Bio Corporate Presentation
Entera Bio Corporate Presentation September 2023

Slide 2: Disclaimer
Disclaimer Various statements in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business

Slide 3: Leader in Orally Administered Protein Therapies
Entera Bio: Leader in Orally Administered Protein Therapies • Proprietary oral delivery technology enables first-in-class, mini tablet formats of protein and peptide replacement therapies • Underserved conditions where oral administration can significantly shift treatment outcomes, versus standard o

Slide 4: Experienced Leadership Team
Experienced Leadership Team 20+ years of biotech C-level leadership and wall street experience; Previously co- Miranda Toledano, MBA founder/COO/CFO TRIGR (Acquired by Compass Therapeutics, Nasdaq: CMPX); Head of HC Chief Executive Officer Investment Banking at MLV/FBR (Acquired B Riley); VP Investm

Slide 5: Clinical & Scientific Advisory Board
Clinical & Scientific Advisory Board Vice-Chair, Department of Medicine for International Research and Education; Chief, Emeritus, of the Division of Professor John P. Bilezikian Endocrinology; Director, Emeritus, of the Metabolic Bone Diseases Program at Columbia University Medical Center Professor

Slide 6: Oral Bioavailability Challenges: Entera Proprietary Oral Delivery Platform
Oral Bioavailability Challenges: Entera Proprietary Oral Delivery Platform Most therapeutic peptides/proteins are SBTI Stabilizes the Protein Administered via IV, SC or IM Injections due to Stability of Peptide in solution in presence of Trypsin proteolytic degradation, variability and lack of 100 P

Slide 7: Entera Oral Delivery of GLP-2 Analog (Teduglutide) Tablets
Entera Oral Delivery of GLP-2 Analog (Teduglutide) Tablets Published May 2023 Oral Tedaglutide Control formulation Oral Tedaglutide Control formulation Teduglutide dose 0.7mg 0.7mg Cmax 17.1 ng/ml 0.6 ng/ml Formulation excipients SNAC+SBTI Mannitol CV% Cmax 19.6% 200% Dosage form Minitablets Minitab

Slide 8: EB613 (oral PTH (1-34), teriparatide)
EB613 (oral PTH (1-34), teriparatide) First Daily Oral Osteoanabolic Mini Tabs for High-Risk, No Prior Fracture Post-Menopausal Women

Slide 9: Osteoporosis Results From An Imbalance In The Bone Remodeling Cycle
Osteoporosis Results From An Imbalance In The Bone Remodeling Cycle That Occurs When Bone Resorption Outpaces Bone Formation Bone Density Healthy vs. Osteoporotic Osteoporosis and the Bone Remodeling Cycle The Bone Remodeling Cycle can be separated into two distinct processes: Resorption (osteoclast

Slide 10: Globally, Osteoporosis Afflicts More Women than Heart Attack, Stroke, and Breast Cancer
Globally, Osteoporosis Afflicts More Women than Heart Attack, Stroke, and Breast Cancer Combined Japan 15 million patients with osteoporosis 20% women over 50 at vs. 5% of men at risk of fracture European Union5 China7 Osteoporosis 70 million patients with osteoporosis United States1-4 25.5 million

Slide 11: Osteoporosis and Menopause
Osteoporosis and Menopause Menopausal transition period Secreted estrogen level Dyslipidemia, hypertension Endometriosis Schematic showing • As hormones change to accommodate Osteoporosis changes in estrogen level with age, normal menopausal changes, estrogen and subsequent disease patterns.3 levels

Slide 12: Healthcare Providers Use T-score BMD Classifications to Drive Therapy Selection
Healthcare Providers (Endo, PCP, GYN) Typically Use T-score BMD Classifications, Patient Fracture History and Preference To Drive Therapy Selection • Injections deter many patients from using extremely effective PTH therapy, contributing to a treatment gap in high-risk patients T-Score Scale • An or

Slide 13: Current Osteoporosis Pharmacologic Treatment: Anti-Resorptive & Anabolic Options
Current Osteoporosis Pharmacologic Treatment Is Segmented Into: Anti-Resorptive & Anabolic Options Stop or slow bone loss Osteoporosis Diagnosis Bone forming Antiresorptive Anabolic ENTERA BIO RANK-Ligand Monoclonal PTH receptor Bisphosphonates Estrogen*/HRT SERMs** Calcitonin Inhibitor Antibodies a

Slide 14: EB613 Phase 2 Results
EB613 Phase 2 Results A Six-Month Study of Oral PTH in Postmenopausal Women with Low Bone Mass – 6 Month Bone Mineral Density (BMD) Results

Slide 15: EB613 Phase 2 Clinical Trial Design
EB613 Phase 2 Clinical Trial Design in High Risk, No Prior Fracture Post- Menopausal Women with Osteoporosis • 6-Month, Randomized Dose-Ranging Placebo-Controlled Study in Post-Menopausal Women with Osteoporosis • Conducted at 4 sites in Israel between June 2019 and May 2021; Final enrollment = 161

Slide 16: EB613: Met Pharmacodynamic Endpoint, Bone Turnover Biomarkers
EB613: Met Pharmacodynamic Endpoint, Bone Turnover Biomarkers • Primary Endpoint: Statistically significant increases in P1NP (key anabolic marker) at Month 1 (p<0.001), Month 2 (p<0.005) and Month 3 (p<0.05), respectively for the 2.5 mg EB613 dose group • Statistically significant decrease in Serum

Slide 17: EB613 Mini Tablets Had Significant Dose Response Across BMD, PK and PD
EB613 Mini Tablets Had Significant Dose Response Across BMD, PK and PD Concentration of hPTH(1-34) in plasma 400 15min post-dose (mean± SE)(pg/ml) EB613 (a.k.a. EBP05, hPTH(1-34) min-tablets) showed a PTH (1-34) 350 linear dose response across PTH exposure, P1NP R² = 0.9961 300 biomarker and BMD Mea

Slide 18: EB613 Increased BMD at All Major Skeletal Sites
EB613 Increased BMD at All Major Skeletal Sites at 6 Months (TH, LS, FN) Placebo adjusted Lumbar Spine BMD • Patients on placebo had decreases in 6 BMD score across all skeletal sites at % change from Day 1 Patients on Placebo had a 0.16% Decrease in LS BMD at 6 months 5 6 months 4 3 2 • EB613 Lumba

Slide 19: EB613 Phase 2 Safety Profile
EB613 Phase 2 Safety Profile Consistent with PTH Targeted Injectables • Adverse event profile - similar to AE profile reported with Forteo and typical of orthostatic hypotension • EB613 not associated with serum calcium increases or hypercalcemia adverse events • 2.5 mg dose with titration (1.5mg f

Slide 20: Osteoporosis Market Overview
Osteoporosis Market Overview Sales and Current Prescription Trends

Slide 21: Anabolic Treated Patients Comprise Less Than 10% of Treated Osteoporosis Patients
Anabolic Treated Patients Comprise Less Than 10% of Currently Treated Osteoporosis Patients, Mostly Very High Risk Patients with Prior Fracture (Endocrinologists and PCPs form majority of the current prescribing base) Population Treated Share of Osteoporosis Treated by Class of Osteoporosis Medicati

Slide 22: EB613 Poised To Create A Paradigm Shift In Osteoporosis Treatment
EB613 Poised To Create A Paradigm Shift In The Treatment of Osteoporosis To Be The First Daily Tablet Anabolic Therapy Forteo® Tymlos® Evenity® Prolia® Bisphosphonates Entera Key Product Needs (Lilly) (Radius) (Amgen) (Amgen) (generics) EB613 Treats Osteoporosis Rebuilds Bone Oral Dosing ENTERA BIO

Slide 23: EB613 Phase 3 Plan and Overview of FDA Process
EB613 Phase 3 Plan and Overview of FDA Process

Slide 24: EB613 Phase 3 Clinical Trial Design
EB613 Phase 3 Clinical Trial Design • Designed with FDA Concurrence (Pursuant to Type C and Type D Meeting) • A Single Global Phase 3, 24-Month Double-Blind, Placebo-Controlled Registrational Study • Total Hip (TH) BMD as Primary Endpoint Screening 24 M Treatment Endpoints Primary – 2:1 Randomizatio

Slide 25: EB613 Phase 3 Clinical Trial Design Uses ASBMR-FNIH STEs
EB613 Phase 3 Clinical Trial Design Uses ASBMR-FNIH STEs • The primary endpoint agreed upon is Mean Change from Baseline in Total Hip BMD of EB613 vs. placebo at 24 months. As a key secondary endpoint, Entera intends to assess this using the pre-defined, published ASBMR- FNIH Surrogate Threshold Eff

Slide 26: Change in Total Hip BMD - Primary Endpoint Analysis for Phase 3
Change in Total Hip BMD - Primary End Point Analysis for Phase 3 EB613 (Titrated 2.5mg dose, Phase 2) vs. FNIH Surrogate Threshold Effects (STEs*) Forteo® (Leder Study) at 6 Months at 24 Months to be Used in EB613 Phase 3 Total Hip BMD 2.5 % BMD Change vs Placebo 2.07 2.13 2 1.83 ENTERA BIO 1.5 1.42

Slide 27: Brief Historical Overview of EB613 Regulatory Trajectory
Brief Historical Overview of EB613 Regulatory Trajectory From End of Phase 2 Mtg 2022 to Date EB613*: Potentially the First Daily Oral PTH Mini Tablets, OsteoAnabolic Treatment for Osteoporosis • June 2021: Phase 2 study met biomarker/PD (P1NP, CTX) and 6-month BMD** endpoints in post- menopausal wo

Slide 28: EB613 Positioning
EB613 Positioning • PTH receptor activation is a validated mechanism of action for treating osteoporosis, as evidenced by FDA/EMA approvals of efficacious agents such as the injectable Forteo® (2002) and Tymlos® (2017) • In this silent disease, patients remain reluctant to take daily injections even

Slide 29: EB612 Oral PTH (1-34) for Hypoparathyroidism
EB612 Oral PTH (1-34) First Daily Oral PTH Mini Tablet Peptide Replacement Therapy for the Treatment of Hypoparathyroidism

Slide 30: Hypoparathyroidism: PTH Orphan Indication with Sub-Par Clinical Care
Hypoparathyroidism: PTH Orphan Indication with Sub-Par Clinical Care Hypoparathyroidism Overview Unmet Need and Market Opportunity Hypoparathyroidism (HypoPT) is a rare condition in which the How many people are affected by HypoPT? parathyroid glands fail to produce sufficient levels of • Approximat

Slide 31: Hypoparathyroidism
Hypoparathyroidism Uninsured <45 years Male 25% 16% 26% Hypoparathyroidism in the United States1,2 ENTERA BIO >45 years Female Insured 74% 75% 84% Symptom severity despite use of calcium and vitamin D2 • Published studies have reported the prevalence of chronic hypoparathyroidism to range from 6.4 t

Slide 32: EB612: Summary of PK and Pilot Phase 2 Data
EB612: Potentially First Oral PTH (1-34) Daily Tablets for Hypoparathyroidism, Summary of PK and Pilot Phase 2 Data Study Design Results Efficacy: Oral Calcium Intake Phase 2a, open-label, multicenter pilot Per Protocol Analysis (N=15) study to evaluate the safety, tolerability and 42% reduction (p=

Slide 33: Entera Next Generation Platform – Current Phase 1 PK/PD Clinical Trial
Entera Next Generation Platform – Current Phase 1 PK/PD Clinical Trial • During 2022, we completed pre-clinical work on proprietary new generations of our oral peptide delivery platform • Potential for curbed dosing of mini tablets across more complex therapeutic proteins and follow-on candidates fo

Slide 34: EB612 Positioning
EB612 Positioning • EB612 is potentially the first oral PTH (1-34) daily tablet peptide replacement therapy for the treatment of hypoparathyroidism • Hypoparathyroidism (HypoPT) is a rare condition in which the parathyroid glands fail to produce sufficient levels of Parathyroid hormone (PTH) • Pilot

Slide 35: Key Recent and Near-Term Milestones
Key Recent and Near-Term Milestones EB613 EB613 EB612 EB613 EB613 ENTERA BIO ✓ FDA Type C FDA Type D PK Data from 2nd Update from FDA Phase 3 Pivotal Meeting onPhase Meeting on Generation Platform ASBMR-FNIH Study Initiation ✓ 3 Design (Executed, Revised Phase 3 Protocol for EB613 and Mini Tab Formu

Slide 36: Thank You
Thank You Contact: Entera Bio: Ms. Miranda Toledano Chief Executive Officer Email: miranda@enterabio.com
Source: Internet Archive copy of enterabio.com
More decks from Entera Bio Ltd.
Technical Presentation (September 2025)19 slides · September 2025
Technical Presentation (July 2025)14 slides · July 2025
Investor Presentation (March 2023)33 slides · March 2023
Investor Presentation (November 2022)34 slides · November 2022
Investor Presentation (November 2022)35 slides · November 2022
Investor Presentation (November 2022)34 slides · November 2022